Daily risedronate prevents bone loss in osteopenic, postmenopausal women:: A 2-year multicenter trial in europe

被引：0
|
作者：
Valmaki, M. [1 ]
Heikkinen, J. [2 ]
Munoz-Torres, M. [3 ]
Mulder, H. [4 ]
Ofjord, E. S. [5 ]
Toss, G. [6 ]
机构：
[1] Univ Helsinki, Cent Hosp, Div Endocrinol, FIN-00014 Helsinki, Finland
[2] Deaconess Inst Oulu, Osteoporosis Clin, Oulu, Finland
[3] Hosp Clin San Cecilio, Granada, Spain
[4] Osteosupport, Rotterdam, Netherlands
[5] Linkoping Univ Hosp, Dept Endocrinol, S-58185 Linkoping, Sweden
[6] Ctr Clin Studies AS, Paradis, Norway
来源：
OSTEOPOROSIS INTERNATIONAL | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S60 / S61
页数：2
相关论文
共 50 条
  • [1] PREVENTION OF EARLY POSTMENOPAUSAL BONE LOSS BY RISEDRONATE - A 2-YEAR STUDY
    MORTENSEN, L
    BEKKER, P
    VANDEROUWELAND, F
    HOROWITZ, Z
    RUPICH, R
    DIGENNARO, J
    AXELROD, D
    JOHNSTON, PCC
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1995, 10 : S140 - S140
  • [2] Risedronate prevents bone loss in early postmenopausal women.
    Ebeling, P
    Roberts, A
    D'Emden, M
    Nicholson, G
    Crusan, C
    Wenderoth, D
    Ethgen, D
    Hooper, M
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S403 - S403
  • [3] Risedronate 5 mg daily for two years prevents bone loss in late postmenopausal women with osteopenia
    不详
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S162 - S162
  • [4] Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women
    Laura D. Bilek
    Nancy L. Waltman
    Joan M. Lappe
    Kevin A. Kupzyk
    Lynn R. Mack
    Diane M. Cullen
    Kris Berg
    Meghan Langel
    Melissa Meisinger
    Ashlee Portelli-Trinidad
    Molly Lang
    [J]. BMC Women's Health, 16
  • [5] Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women
    Bilek, Laura D.
    Waltman, Nancy L.
    Lappe, Joan M.
    Kupzyk, Kevin A.
    Mack, Lynn R.
    Cullen, Diane M.
    Berg, Kris
    Langel, Meghan
    Meisinger, Melissa
    Portelli-Trinidad, Ashlee
    Lang, Molly
    [J]. BMC WOMENS HEALTH, 2016, 16
  • [6] Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial
    Hooper, MJ
    Ebeling, PR
    Roberts, AP
    Graham, JJ
    Nicholson, GC
    D'Emden, M
    Ernst, TF
    Wenderoth, D
    [J]. CLIMACTERIC, 2005, 8 (03) : 251 - 262
  • [7] Effects of 2-year treatment with risedronate in postmenopausal osteoporosis
    Sendur, O. F.
    Gurer, G.
    Aydemir, A. H.
    Tastaban, E.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S267 - S268
  • [8] Risedronate prevents bone loss in breast cancer survivors: A 2-year, randomized, double-blind, placebo-controlled clinical trial
    Greenspan, Susan L.
    Brufsky, Adam
    Lembersky, Barry C.
    Bhattacharya, Rajib
    Vujevich, Karen T.
    Perera, Subashan
    Sereika, Susan M.
    Vogel, Victor G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (16) : 2644 - 2652
  • [9] Longitudinal Alveolar Bone Loss in Postmenopausal Osteoporotic/Osteopenic Women
    J. B. Payne
    R. A. Reinhardt
    P. V. Nummikoski
    K. D. Patil
    [J]. Osteoporosis International, 1999, 10 : 34 - 40
  • [10] Longitudinal alveolar bone loss in postmenopausal osteoporotic/osteopenic women
    Payne, JB
    Reinhardt, RA
    Nummikoski, PV
    Patil, KD
    [J]. OSTEOPOROSIS INTERNATIONAL, 1999, 10 (01) : 34 - 40
12345